BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte (PCVX)VaxcyteCompany update

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences: Wells Fargo 21 st Annual

Related news

PCVXVaxcyte2026-03-18 23:34 EST

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

PCVXVaxcyte2026-09-03 20:05 EST

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

VXRTVaxart2026-07-21 12:00 EST

Vaxart to Participate in BTIG Biotechnology Conference 2026

VXRTVaxart2026-06-09 12:00 EST

Vaxart to Participate in BTIG Infectious Disease Day 2026

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-09-03 20:05 EST

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

PCVXVaxcyte2026-08-27 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Stock data

Close
60.37 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States